哈佛生物科學 HBIO 深 滬
等待開盤 03-26 09:30:00 美东时间
5.13
0.000
0.00%
華盛通- 最 高5.19
- 今 開5.19
- 成交量 1.68万股
- 最 低 5.02
- 昨 收 5.13
- 總市值 2.29亿
- 52周最高 9.458
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 2.813
- 委 比 4.31%
- 總股本 4471.99万
- 歷史最高 87.50
- 量 比 0.27
- 振 幅 3.31%
- 歷史最低 2.813
- 每 手 1
- 風險率 1.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
03-13 20:48
Harvard Bioscience Sees Q1 Sales $20.000M-$22.000M vs $21.250M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q1 sales of $20.000 million-$22.000 million vs $21.250 million analyst estimate.
03-12 19:32
Harvard Bioscience Q4 Sales $23.735M Beat $23.100M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $23.735 million which beat the analyst consensus estimate of $23.100 million by 2.75 percent. This is a 3.34 percent decrease over sales of $24.556 million
03-12 19:31
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Zevra Therapeutics (NASDAQ:ZVRA) stock moved upwards by 20.6% to $11.0...
03-10 05:05
Harvard Bioscience Board Approves 1-For-10 Reverse Stock Split, Effective March 13
Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the
03-07 05:04
Harvard Bioscience shares are trading higher after the company reported preliminary Q4 results, issued FY26 outlook and outlined its long-term strategic focus areas.
Harvard Bioscience shares are trading higher after the company reported prelimi...
02-11 00:41
Harvard Bioscience Reports Q4 Preliminary Revenue Of $23.7M
Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter ended December 31,
02-10 20:38
